Treatment of non-complicated Horton's disease;Traitement de la maladie de Horton simple

Revue du Praticien

Volumn 49, Issue 6, 1999, Pages 613-617

  Sailler, Laurent ^a   Juchet, Henri ^a   Arlet, Philippe ^a  

^a CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CORTICOSTEROID; PREDNISOLONE; PREDNISONE;

ATHEROSCLEROSIS; BLEEDING; CLINICAL FEATURE; DRUG EFFICACY; HUMAN; OSTEOPOROSIS; REVIEW; TEMPORAL ARTERITIS; TREATMENT INDICATION;

ADRENAL CORTEX HORMONES; ARTERIOSCLEROSIS; HUMANS; OSTEOPOROSIS; TEMPORAL ARTERITIS;

EID: 0033559472     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Achkar AA, Lie JT, Hunder GG, O'Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant-cell (temporal) arteritis ? Ann Intern Med 1994 ; 120 : 987-92.
2. Chevalet P, Pottier P, Planchon B et al. Protocole SNFMI multicentrique sur l'utilisation des bolus IV de méthylprednisolone, à la période d'attaque de la maladie de Horton simple : résultats définitifs à I an (164 patients). Rev Med Interne 1998 ; 19 (suppl. 1) : 87s.
3. Liozon E, Venot J, Liozon F et al. Les protéines de l'inflammation au cours de la maladie de Horton. Étude prospective chez 25 patients. Ann Med Interne 1990 ; 141 : 319-24.
4. Bisgard C, Sloth H, Kelding N et al. Excess mortality in giant-cell arteritis. J Intern Med 1991 ; 230 : 119-23.
5. Liozon F, Catanzano G. L'artérite temporale de Horton. Étude anatomopathologique en microscopie optique. À propos de 123 biopsies temporales. Rev Med Interne 1982 ; 3 : 295-301.
6. Grau RG, Kassan SS, Franks JJ et al. Fibrino (geno) lysis in polymyalgia rheumatica and temporal arteritis : preliminary findings on association with disease activity. Ann Rheum Dis 1984 ; 43 : 71-24.
7. Nordborg E, Andersson R, Tengborn L et al. Von Willebrand-factor antigen and plasminogen activator inhibitor in giant-cell arteritis. Ann Rheum Dis 1991 ; 50 : 316-20.
8. Espinoza LR, Jara LJ, Silveira LH et al. Anticardiolipin antibodies in polymyalgia rheumatica and giant-cell arteritis : association with severe complications. Am J Med 1991 ; 90 : 474-8.
9. Kaiser M, Weyand CM, Bjornsonn J, Goronzy JJ. Platelet-derived growth factor, intimal hyperplasia, and ischemic complication in giant-cell arteritis. Arthritis Rheum 1998 ; 41 : 623-33.
10. Duhaut P, Berruyer M, Pinède L et al. Anticardiolipin antibodies and giant-cell arteritis : a prospective, multicenter, case-control study. Arthritis Rheum 1998 ; 41 : 701-9.
11. Liozon F, Vidal E, Boutros-Toni F et al. Evolution de la maladie de Horton. A propos de 42 malades guéris. Ann Med Interne 1994 ; 145 : 223-9.
12. Barrier J, Tournemaine N, Maulaz D et al. Evolution, traitement et pronostic de la maladie de Horton. Ann Med Interne 1983 ; 134 : 428-35.
13. Gouet D, Mar,chaud R, Le Berre D et al. Pronostic de l'artérite temporale traitée. Étude rétrospective de 87 observations. Presse Med 1986 ; 15 : 603-6.
14. Penin F, Hingray C, Tagu P, Cuny G. Évolution sous traitement de la maladie de Horton. A propos d'une serie de 60 observations. Med Hyg 1983 ; 41 : 1901-9.
15. Godeau P, Aubert L, Guillevin L et al. Aspects cliniques, évolution et pronostic de la maladie de Horton. Étude rétrospective de 47 observations. Ann Med Intern 1982 ; 133 : 393-400.
16. Huston KA, Hunder GG, Lie JT, Kennedy RH. Temporal arteritis. A 25-years epidemiologic, clinical, and pathologic study. Ann Intern Med 1978 ; 88 : 162-7.
17. Piton JL, Zagala A, Rebuffet JL et al. Maladie de Horton et pseudo-polyarthrite rhizomélique. Données évolutives. À propos de 95 cas. Rev Rhum Mal Osteoartic 1987 ; 54 : 7-13.
18. Conn HO, Poynard T. Corticosteroid and peptic ulcer : meta-analysis of adverse events during steroid therapy. J Intern Med 1994 ; 236 : 619-32.
19. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996 ; 39 : 1791-801.
20. Werth VP. Glucocorticoid-induced osteoporosis : prevention and treatment Rev Rhum (ed. angl.) 1997 ; 64 : 84S-88S.
21. Adachi JD, Bensen WG, Brown J et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997 ; 337 : 382-7.
22. Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate : a randomized trial. Calcif Tissue Int 1997 ; 61 : 266-71.
23. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994 ; 33 : 348-50.
24. Struys A, Snelder AA, Mulder H et al. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995 ; 99 : 235-42.
25. Nordborg E, Schaufelberger C, Andersson R, Bosaeus I, Bengtsson BA. The ineffectiveness of cyclical oral clodronate on bone mineral density in glucocorticoid-treated patients with giant-cell arteritis. J Intern Med 1997 ; 242 : 367-71.
26. Prevention of pneumococcal disease. Recommendations of the Adversory Comittee on Immunization Practice (ACIP). Morb Mortal Wkly Rep 1997 ; 46 : 1-24.
27. Carrie F, Roblot P, Bouquet S, Delon A, Roblot F, Becq-Giraudon B. Rifampicin-induced non responsiveness of giant-cell arteritis to prednisone treatment. Arch Intern Med 1994 ; 154 : 1521-4.
28. LeGuennec P, Dromer C, Sixou L, Marc V, Coustals P, Fourni, B. Traitement de la maladie de Horton : interêt des antipaludéens de synthèse. Rev Rhum (ed. fr.) 1994 ; 61 : 485-90.
29. Feinberg HL, Shermann JD, Schrepfermann CG, Dietzen CJ, Feinberg GD. The use of methotrexate in polymyalgia rheumatica. J Rheumatol 1996 ; 23 : 1550-2.
30. Van der Veen MJ, Dinan HJ, Van-Booma Francfort C, Van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used in the treatment of polymyalgia rheumatica and giant-cell arteritis? Ann Rheum Dis 1996 ; 55 : 218-23.